Rituximab in pemphigus and pemphigoid patients: Treatment outcomes and safety profile - A 6-year tertiary center study
Background: Pemphigus and pemphigoid are autoimmune blistering disorders characterized by autoantibodies attacking skin and mucous membranes. Rituximab, targeting CD20-positive B cells, has emerged as a treatment option for resistant cases. Aims and Objectives: To evaluate the treatment outcomes...
Saved in:
| Main Authors: | Sivakanth Gopakumar, Nima Teresa Andrew, Maria Jose, Sanitha Kuriachan, Jumi Jacob |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Manipal College of Medical Sciences, Pokhara
2025-07-01
|
| Series: | Asian Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://ajmsjournal.info/index.php/AJMS/article/view/4588 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enfortumab vedotin therapy complicated by bullous dermatitis: A case report
by: Roxana A. Hojjatie, BS, et al.
Published: (2025-07-01) -
Ofatumumab for the management of refractory pemphigus vulgaris: A case series
by: Sera Sarsam, MBBS, BMedSc, et al.
Published: (2025-10-01) -
Meeting Report on “10th Anniversary Symposium on Inflammatory Skin Disease”
by: Shirin Emtenani, et al.
Published: (2025-05-01) -
A Case of Recurrent Pemphigus Foliaceus Following Noncompliance to Medication
by: Masab Ali, et al.
Published: (2024-11-01) -
Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases
by: Liliana Gabriela Popa, et al.
Published: (2024-09-01)